Loading…

Epigallocatechin Gallate (EGCG) and Rutin Suppress the Glucotoxicity through Activating IRS2 and AMPK Signaling in Rat Pancreatic β Cells

Pancreatic β cell failure is one critical metabolic disorder in the development of type 2 diabetes. Decreased viability and dysfunction of β cells would accelerate the diabetic pathogenesis associated with higher mortality. In this study, the tea polyphenol EGCG (epigallocatechin gallate) and the bu...

Full description

Saved in:
Bibliographic Details
Published in:Journal of agricultural and food chemistry 2009-10, Vol.57 (20), p.9817-9827
Main Authors: Cai, Erica P, Lin, Jen-Kun
Format: Article
Language:English
Subjects:
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Pancreatic β cell failure is one critical metabolic disorder in the development of type 2 diabetes. Decreased viability and dysfunction of β cells would accelerate the diabetic pathogenesis associated with higher mortality. In this study, the tea polyphenol EGCG (epigallocatechin gallate) and the buckwheat flavonoid Rutin were investigated to attenuate the induced glucotoxicity in β cells. EGCG and Rutin could preserve the insulin secretory machinery and stimulate insulin receptor substrate 2 (IRS2) signaling in rat pancreatic β cells, RIN-m5F. These findings further demonstated the reduced glucolipotoxic effects of EGCG and Rutin through activating AMP-activated protein kinase (AMPK) signaling to inhibit the activities of lipogenic enzymes and ameliorating mitochondrial function. Consequently, the cell viability was retained after attenuating the glucotoxicity through the broad effect of EGCG and Rutin. The intrinsic protective effects of EGCG and Rutin in preserving the insulin signaling and regulating lipogenesis, manipulating cell cycling, and maintaining mitochondrial function to achieve the integrity of β cells, which highlight the possibilities of EGCG and Rutin as novel strategies for the prevention of type 2 diabetes.
ISSN:0021-8561
1520-5118
DOI:10.1021/jf902618v